Journal of Ophthalmology · 2019 · 56 citations · 39 references
MedicineOphthalmologyPharmacologyClinical OptometryMyopia ManagementOcular PharmacologyAtropine TherapyChoroidal ChangesMedication Effects On VisionMyopia ControlOcular PharmacodynamicsPathophysiology Of MyopiaAtropine UseChoroidal Thickness MeasurementChoroidal Thickness ResponseDefocusDose-response Of AtropineLow-dose Atropine TherapyOcular BiometricsSubfoveal Choroidal Thickness
Purpose . To examine the interaction between a short period of hyperopic defocus and low-dose atropine upon the choroidal thickness and ocular biometrics of healthy myopic subjects. Methods . Twenty young adult myopic subjects had subfoveal choroidal thickness (ChT) and ocular biometry measurements taken before and 30 and 60 min following the introduction of optical blur (0.00 D and −3.00 D) combined with administration of 0.01% atropine or placebo. Each combination of optical blur and drug was tested on different days in a fixed order. Results . The choroid exhibited significant thinning after imposing hyperopic defocus combined with placebo (mean change of −11 ± 2 μ m, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math>). The combination of hyperopic blur and 0.01% atropine led to a significantly smaller magnitude of subfoveal choroidal thinning (−4 ± 8 μ m), compared to placebo and hyperopic defocus (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math>). Eyes treated with 0.01% atropine with no defocus exhibited a significant increase in ChT (+6 ± 2 μ m, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math>). Axial length also underwent small but significant changes after treatment with hyperopic blur and placebo and 0.01% atropine alone (both <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math>), but of opposite direction to the changes in choroidal thickness. However, the 0.01% atropine/hyperopic blur condition did not lead to a significant change in axial length compared to baseline (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mrow><mml:mi>p</mml:mi><mml:mo>></mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math>). Conclusion . Low-dose atropine does inhibit the short-term effect of hyperopic blur on choroidal thickness and, when used alone, does cause a slight thickening of the choroid in young healthy myopic adults.
39
Efficacy Comparison of 16 Interventions for Myopia Control in Children
Jinhai Huang, Daizong Wen, Qinmei Wang et al. · Ophthalmology · 2016 · 758 citations · Full text
Medicine, Ophthalmology, Pediatrics +17
Low-Concentration Atropine for Myopia Progression (LAMP) Study
Jason C. Yam, Yuning Jiang, Shu Min Tang et al. · Ophthalmology · 2018 · 694 citations
Medicine, Ophthalmology, Optometry +14
Atropine for the Treatment of Childhood Myopia
Wei‐Han Chua, Vivian Balakrishnan, Yiong‐Huak Chan et al. · Ophthalmology · 2006 · 679 citations
Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2
Audrey Chia, Qingshu Lu, Donald Tan · Ophthalmology · 2015 · 634 citations · Full text